FindTrial
Sign In

Study on Carbapenem Resistance in India

A multicentric Retrospective Analysis of Prevalence, Risk factors, Treatment patterns and Outcome Predictors of Carbapenem Resistance in India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/01/007698
Enrollment
1500
Registered
2017-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hospital admitted

Interventions

None listed

Sponsors

MSD Pharmaceuticals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients admitted in the ICU & Wards from Jan â?? Dec 2015 & whose culture samples were tested for Group 1 &/or 2 carbapenems. • Samples from clinical infections/sterile sites (Pleura, pericardium, peritoneum, CSF, Blood & non catheterized urine). • All community (resistance +ve less than 48 hrs from admission) & hospital acquired (resistance +ve more than 48 hrs from admission) carbapenem & colistin resistant cases.

Exclusion criteria

Exclusion criteria: • Samples from potential colonization sites like skin swabs, pus, sputum & catheterized urine (to eliminate colonizers

Design outcomes

Primary

MeasureTime frame
i.mortality ii.clinical improvementTimepoint: One yr—

Secondary

MeasureTime frame
i.Hospital stay ii.Stay in ICU iii.biomarkers(if any)Timepoint: One yr—

Countries

India

Contacts

Public ContactDr Raja Dhar

Fortis Hospital, Anandapur,Kolkata

docaardee@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026